However, many pathology laboratories do not have access to the Autostainer Link 48 and therefore cannot use PD-L1 IHC 22C3 pharmDx to assess the PD-L1 tumor status of patients who may be candidates for treatment with pembrolizumab. Here, CD274 is linked to neoplasm.